These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

745 related items for PubMed ID: 16399209

  • 1. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB, Lavados M, Guillón M, Mujica C, Bosch R, Farías G, Fuentes P.
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [Abstract] [Full Text] [Related]

  • 2. ApoE alleles and tau markers in patients with different levels of cognitive impairment.
    Lavados M, Farías G, Rothhammer F, Guillon M, Mujica MC, Maccioni C, Maccioni RB.
    Arch Med Res; 2005 Feb; 36(5):474-9. PubMed ID: 16099324
    [Abstract] [Full Text] [Related]

  • 3. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [Abstract] [Full Text] [Related]

  • 4. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
    Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kölsch H, Jessen F, Schröder J, Schönknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J.
    Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
    [Abstract] [Full Text] [Related]

  • 5. Increased total TAU but not amyloid-beta(42) in cerebrospinal fluid correlates with short-term memory impairment in Alzheimer's disease.
    Lin YT, Cheng JT, Yao YC, Juo, Lo YK, Lin CH, Ger LP, Lu PJ.
    J Alzheimers Dis; 2009 Jun; 18(4):907-18. PubMed ID: 19749420
    [Abstract] [Full Text] [Related]

  • 6. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, Pierantozzi M.
    J Neurol Sci; 2006 Dec 21; 251(1-2):124-8. PubMed ID: 17097109
    [Abstract] [Full Text] [Related]

  • 7. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM.
    Neurology; 2009 Mar 24; 72(12):1056-61. PubMed ID: 19307538
    [Abstract] [Full Text] [Related]

  • 8. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.
    Biol Psychiatry; 2004 Nov 01; 56(9):670-6. PubMed ID: 15522251
    [Abstract] [Full Text] [Related]

  • 9. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
    Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, Hack CE, Veerhuis R.
    J Alzheimers Dis; 2010 Nov 01; 20(1):253-60. PubMed ID: 20164582
    [Abstract] [Full Text] [Related]

  • 10. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H.
    J Intern Med; 2004 Sep 01; 256(3):205-23. PubMed ID: 15324364
    [Abstract] [Full Text] [Related]

  • 11. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM.
    Arch Neurol; 2007 Mar 01; 64(3):343-9. PubMed ID: 17210801
    [Abstract] [Full Text] [Related]

  • 12. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.
    J Alzheimers Dis; 2010 Mar 01; 21(2):471-8. PubMed ID: 20555147
    [Abstract] [Full Text] [Related]

  • 13. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.
    Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM, Scheltens P.
    Neurobiol Aging; 2010 May 01; 31(5):758-64. PubMed ID: 18692273
    [Abstract] [Full Text] [Related]

  • 14. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.
    Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ.
    Neurology; 2007 Aug 14; 69(7):631-9. PubMed ID: 17698783
    [Abstract] [Full Text] [Related]

  • 15. Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.
    Nordlund A, Rolstad S, Klang O, Lind K, Pedersen M, Blennow K, Edman A, Hansen S, Wallin A.
    J Int Neuropsychol Soc; 2008 Jul 14; 14(4):582-90. PubMed ID: 18577287
    [Abstract] [Full Text] [Related]

  • 16. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K, Hansson O, Buchhave P, Zetterberg H, Lewczuk P, Londos E, Blennow K, Minthon L, Wiltfang J.
    Neurodegener Dis; 2008 Jul 14; 5(5):268-76. PubMed ID: 18309230
    [Abstract] [Full Text] [Related]

  • 17. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.
    Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, Matsui T, Higuchi S, Matsushita S, Yoshida H, Sasaki H.
    Exp Neurol; 2001 Dec 14; 172(2):433-6. PubMed ID: 11716567
    [Abstract] [Full Text] [Related]

  • 18. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
    Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P.
    Mech Ageing Dev; 2006 Feb 14; 127(2):129-32. PubMed ID: 16274728
    [Abstract] [Full Text] [Related]

  • 19. Subcortical vascular dementia biomarker pattern in mild cognitive impairment.
    Bjerke M, Andreasson U, Rolstad S, Nordlund A, Lind K, Zetterberg H, Edman A, Blennow K, Wallin A.
    Dement Geriatr Cogn Disord; 2009 Feb 14; 28(4):348-56. PubMed ID: 19864909
    [Abstract] [Full Text] [Related]

  • 20. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.
    de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Rusinek H, Li J, Tsui W, Saint Louis LA, Clark CM, Tarshish C, Li Y, Lair L, Javier E, Rich K, Lesbre P, Mosconi L, Reisberg B, Sadowski M, DeBernadis JF, Kerkman DJ, Hampel H, Wahlund LO, Davies P.
    Neurobiol Aging; 2006 Mar 14; 27(3):394-401. PubMed ID: 16125823
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.